Latest news with #personalizedMedicine
Yahoo
26-05-2025
- Business
- Yahoo
Proteomics Market Global and Regional Analysis and Forecasts, 2024-2025 & 2034: Increasing Automation for End-to-End Proteomics Workflow, Significant Number of Collaborations Among Market Players
Key growth catalysts include advancements in mass spectrometry and next-generation sequencing, heightened demand for personalized medicine, increased research funding, and strategic collaborations. With applications in drug discovery, diagnostics, and personalized medicine, the market is expanding rapidly across regions, particularly in Asia-Pacific, fueled by significant healthcare and biotech investments. Notable players include Danaher, Thermo Fisher, and Agilent Technologies, all focusing on innovative solutions. Proteomics Market Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Proteomics Market - A Global and Regional Analysis: Focus on Offerings, Application, End User, and Region - Analysis and Forecast, 2024-2034" report has been added to global proteomics market is projected to reach $109.71 billion by 2034 from $33.92 billion in 2024, growing at a CAGR of 12.46% during the forecast period 2024-2034. Key factors driving this growth include technological advancements in mass spectrometry and next-generation sequencing, which improve the accuracy of proteomics analysis. The rising demand for personalized medicine, particularly for biomarker discovery and disease profiling, is another major driver. Additionally, increased research funding, strategic collaborations, and the need for early disease detection and effective diagnostics further support market expansion. With an aging population and a higher prevalence of chronic diseases, the demand for proteomics in healthcare and research is expected to continue to rise, ensuring the market sustained growth. Proteomics has significantly advanced disease understanding by uncovering molecular mechanisms in conditions like cancer, cardiovascular, and neurological disorders. It plays a vital role in biomarker discovery, enabling early, precise, and non-invasive diagnostics. In personalized medicine, proteomics supports tailored treatment strategies based on individual protein profiles. The field also aids drug development by identifying new targets and facilitating the study of protein-therapeutic interactions. Clinically, proteomics improves disease monitoring, treatment planning, and therapeutic assessments. Additionally, it drives technological innovation in analytical tools such as mass spectrometry and protein arrays, influencing broader scientific market is expanding in regions such as North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa, with Asia-Pacific experiencing rapid growth due to increasing investments in healthcare and biotechnology. Together, these elements drive the continued evolution and growth of the proteomics market globally. China dominated the Asia-Pacific proteomics market in 2022, driven by several key factors. The country has made substantial investments in healthcare, biotechnology, and life sciences research, positioning itself as a leader in the region. China robust infrastructure, large population, and government initiatives, such as the ""Made in China 2025 plan, which emphasizes technological innovation, have further accelerated advancements in proteomics addition, China has become a hub for pharmaceutical and biotechnology companies, fostering an environment conducive to research and development in areas such as drug discovery, personalized medicine, and biomarker identification. The growing demand for proteomics in clinical diagnostics, coupled with the country increasing focus on precision medicine, has bolstered market the rapid adoption of advanced proteomics technologies, such as mass spectrometry and next-generation sequencing, has allowed China to expand its research capabilities and enhance its position in the global market. With a strong emphasis on improving healthcare outcomes and expanding its scientific capabilities, China is expected to continue to lead the proteomics market in the Asia-Pacific region for the foreseeable future. Market Segmentation Highlights Based on offering, the proteomics market is led by product, which held a 72.53% share in 2022. Based on application, the proteomics market is led by drug discovery, which held a 53.64% share in 2022. Based on end user, the proteomics market is led by academic and research institutions, which held a 51.50% share in 2022. Key Market Players Danaher Corporation Thermo Fisher Scientific, Inc. Agilent Technologies, Inc. Bio-rad Laboratories Revvity, Inc. Illumina, Inc. DiaSorin S.p.A. Takara Bio Inc. Merck KGaA Key Attributes: Report Attribute Details No. of Pages 176 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $33.92 Billion Forecasted Market Value (USD) by 2034 $109.71 Billion Compound Annual Growth Rate 12.4% Regions Covered Global Key Topics Covered: Executive SummaryScope and Definition1 Market1.1 Market Outlook1.1.1 Comparative Advantages and Disadvantages of Proteomics Over Other Omics1.1.2 Proteomics Techniques by Introduction with Principles and Advantages/Limitations1.2 Key Findings1.3 Proteomics Market Scenario1.3.1 Realistic Scenario1.3.2 Optimistic Scenario1.3.3 Pessimistic Scenario1.4 Industry Outlook1.4.1 Supply Chain Overview1.5 Trends: Current and Future Impact Assessment1.5.1 Increasing Automation for End-to-End Proteomics Workflow1.5.2 Significant Number of Collaborations among Market Players1.5.3 Growing Proteomics Research to Identify Disease Biomarkers1.6 Patent Analysis1.6.1 Patent Filing Trend (by Country, Year)1.7 Regulatory Framework1.7.1 U.S.1.7.1.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.1.2 Regulatory Requirements for Research Use Only (RUO) Products1.7.1.3 Requirements under the Clinical Laboratory Improvement Amendments (CLIA) for Clinical Proteomics Labs1.7.2 European Union (EU)1.7.2.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.2.1.1 EU Medical Device Regulation1.7.2.1.2 EU In Vitro Diagnostic Regulation1.7.2.2 Regulatory Requirements for Clinical Proteomics Labs in the EU1.7.3 Japan1.7.3.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.3.2 Regulatory Requirements for Clinical Proteomics Labs in Japan1.7.4 China1.7.4.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.5 Brazil1.7.5.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.5.2 Regulatory Requirements for Clinical Proteomics Labs in Brazil1.8 Product Benchmarking1.9 Market Dynamics Overview1.9.1 Market Drivers1.9.1.1 Increasing Prevalence of Chronic Diseases1.9.1.2 Increasing Technological Advancements1.9.1.3 Advancements in Personalized Medicine and Drug Discovery1.9.2 Market Restraints1.9.2.1 Shortage of Skilled Professionals1.9.2.2 Complexity in Analyzing Data of Proteomics Research1.9.3 Market Opportunities1.9.3.1 Progress in Nanoproteomics Platforms to Enhance and Thoroughly Analyze Natural Protein Complexes2 Global Proteomics Market (by Offering), $Million, 2022-20342.1 Product2.1.1 Kits and Reagents2.1.2 Instruments2.1.2.1 Spectroscopy2.1.2.2 Chromatography2.1.2.3 Electrophoresis2.1.2.4 Others2.1.3 Software2.2 Service3 Global Proteomics Market (by Application), $Million, 2022-20343.1 Drug Discovery3.2 Clinical Diagnostics3.2.1 Cancer3.2.2 Infectious Disease3.2.3 Others3.3 Others4 Global Proteomics Market (by End User), $Million, 2022-20344.1 Biopharmaceutical Companies4.2 Academic and Research Institutions4.3 Hospitals and Diagnostic Laboratories4.4 Others5 Global Proteomics Market (by Region), $Million, 2022-20345.1 Regional Summary5.2 North America5.2.1 Regional Overview5.2.2 Driving Factors for Market Growth5.2.3 Factors Challenging the Market5.2.4 North America Proteomics Market, by Application5.2.5 North America Proteomics Market, by Offering5.2.5.1 North America Proteomics Market, by Product5.2.6 U.S.5.2.7 Canada5.3 Europe5.4 Asia-Pacific5.5 Latin America5.6 Middle East and Africa6 Global NGS in Proteomics Market6.1 NGS in Proteomics6.1.1 Purpose of NGS in Proteomics6.1.2 Application of NGS in Proteomics6.1.2.1 Advantages of NGS-based Proteomics6.1.2.2 Challenges in NGS-based Proteomics6.1.2.3 Future Trends of NGS in Proteomics6.1.3 NGS in Large-Scale Proteomics6.2 Market Sizing and Forecast6.2.1 By Application6.2.2 By End User7 Markets - Competitive Benchmarking & Company Profiles7.1 Global Proteomics Market: Competitive Landscape7.1.1 Corporate Strategies, January 2022-December 20247.1.2 Partnerships, Alliances, and Business Expansions7.1.3 Mergers and Acquisitions7.1.4 New Offerings7.2 Company Profiles7.2.1 Overview7.2.2 Top Products/Services7.2.3 Top Competitors7.2.4 Target Customers7.2.5 Key Personnel7.2.6 Analyst View Agilent Technologies, Inc. Applied Biomics Biognosys AG Bio-Rad Laboratories, Inc. Danaher Corporation DiaSorin S.p.A. Illumina, Inc. Merck KGaA MS Bioworks Promega Corporation Oxford Expression Technologies Ltd. Revvity, Inc. Standard BioTools Inc. Takara Bio Inc. Thermo Fisher Scientific Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Proteomics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-05-2025
- Business
- Yahoo
Proteomics Market Global and Regional Analysis and Forecasts, 2024-2025 & 2034: Increasing Automation for End-to-End Proteomics Workflow, Significant Number of Collaborations Among Market Players
Key growth catalysts include advancements in mass spectrometry and next-generation sequencing, heightened demand for personalized medicine, increased research funding, and strategic collaborations. With applications in drug discovery, diagnostics, and personalized medicine, the market is expanding rapidly across regions, particularly in Asia-Pacific, fueled by significant healthcare and biotech investments. Notable players include Danaher, Thermo Fisher, and Agilent Technologies, all focusing on innovative solutions. Proteomics Market Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Proteomics Market - A Global and Regional Analysis: Focus on Offerings, Application, End User, and Region - Analysis and Forecast, 2024-2034" report has been added to global proteomics market is projected to reach $109.71 billion by 2034 from $33.92 billion in 2024, growing at a CAGR of 12.46% during the forecast period 2024-2034. Key factors driving this growth include technological advancements in mass spectrometry and next-generation sequencing, which improve the accuracy of proteomics analysis. The rising demand for personalized medicine, particularly for biomarker discovery and disease profiling, is another major driver. Additionally, increased research funding, strategic collaborations, and the need for early disease detection and effective diagnostics further support market expansion. With an aging population and a higher prevalence of chronic diseases, the demand for proteomics in healthcare and research is expected to continue to rise, ensuring the market sustained growth. Proteomics has significantly advanced disease understanding by uncovering molecular mechanisms in conditions like cancer, cardiovascular, and neurological disorders. It plays a vital role in biomarker discovery, enabling early, precise, and non-invasive diagnostics. In personalized medicine, proteomics supports tailored treatment strategies based on individual protein profiles. The field also aids drug development by identifying new targets and facilitating the study of protein-therapeutic interactions. Clinically, proteomics improves disease monitoring, treatment planning, and therapeutic assessments. Additionally, it drives technological innovation in analytical tools such as mass spectrometry and protein arrays, influencing broader scientific market is expanding in regions such as North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa, with Asia-Pacific experiencing rapid growth due to increasing investments in healthcare and biotechnology. Together, these elements drive the continued evolution and growth of the proteomics market globally. China dominated the Asia-Pacific proteomics market in 2022, driven by several key factors. The country has made substantial investments in healthcare, biotechnology, and life sciences research, positioning itself as a leader in the region. China robust infrastructure, large population, and government initiatives, such as the ""Made in China 2025 plan, which emphasizes technological innovation, have further accelerated advancements in proteomics addition, China has become a hub for pharmaceutical and biotechnology companies, fostering an environment conducive to research and development in areas such as drug discovery, personalized medicine, and biomarker identification. The growing demand for proteomics in clinical diagnostics, coupled with the country increasing focus on precision medicine, has bolstered market the rapid adoption of advanced proteomics technologies, such as mass spectrometry and next-generation sequencing, has allowed China to expand its research capabilities and enhance its position in the global market. With a strong emphasis on improving healthcare outcomes and expanding its scientific capabilities, China is expected to continue to lead the proteomics market in the Asia-Pacific region for the foreseeable future. Market Segmentation Highlights Based on offering, the proteomics market is led by product, which held a 72.53% share in 2022. Based on application, the proteomics market is led by drug discovery, which held a 53.64% share in 2022. Based on end user, the proteomics market is led by academic and research institutions, which held a 51.50% share in 2022. Key Market Players Danaher Corporation Thermo Fisher Scientific, Inc. Agilent Technologies, Inc. Bio-rad Laboratories Revvity, Inc. Illumina, Inc. DiaSorin S.p.A. Takara Bio Inc. Merck KGaA Key Attributes: Report Attribute Details No. of Pages 176 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $33.92 Billion Forecasted Market Value (USD) by 2034 $109.71 Billion Compound Annual Growth Rate 12.4% Regions Covered Global Key Topics Covered: Executive SummaryScope and Definition1 Market1.1 Market Outlook1.1.1 Comparative Advantages and Disadvantages of Proteomics Over Other Omics1.1.2 Proteomics Techniques by Introduction with Principles and Advantages/Limitations1.2 Key Findings1.3 Proteomics Market Scenario1.3.1 Realistic Scenario1.3.2 Optimistic Scenario1.3.3 Pessimistic Scenario1.4 Industry Outlook1.4.1 Supply Chain Overview1.5 Trends: Current and Future Impact Assessment1.5.1 Increasing Automation for End-to-End Proteomics Workflow1.5.2 Significant Number of Collaborations among Market Players1.5.3 Growing Proteomics Research to Identify Disease Biomarkers1.6 Patent Analysis1.6.1 Patent Filing Trend (by Country, Year)1.7 Regulatory Framework1.7.1 U.S.1.7.1.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.1.2 Regulatory Requirements for Research Use Only (RUO) Products1.7.1.3 Requirements under the Clinical Laboratory Improvement Amendments (CLIA) for Clinical Proteomics Labs1.7.2 European Union (EU)1.7.2.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.2.1.1 EU Medical Device Regulation1.7.2.1.2 EU In Vitro Diagnostic Regulation1.7.2.2 Regulatory Requirements for Clinical Proteomics Labs in the EU1.7.3 Japan1.7.3.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.3.2 Regulatory Requirements for Clinical Proteomics Labs in Japan1.7.4 China1.7.4.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.5 Brazil1.7.5.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.5.2 Regulatory Requirements for Clinical Proteomics Labs in Brazil1.8 Product Benchmarking1.9 Market Dynamics Overview1.9.1 Market Drivers1.9.1.1 Increasing Prevalence of Chronic Diseases1.9.1.2 Increasing Technological Advancements1.9.1.3 Advancements in Personalized Medicine and Drug Discovery1.9.2 Market Restraints1.9.2.1 Shortage of Skilled Professionals1.9.2.2 Complexity in Analyzing Data of Proteomics Research1.9.3 Market Opportunities1.9.3.1 Progress in Nanoproteomics Platforms to Enhance and Thoroughly Analyze Natural Protein Complexes2 Global Proteomics Market (by Offering), $Million, 2022-20342.1 Product2.1.1 Kits and Reagents2.1.2 Instruments2.1.2.1 Spectroscopy2.1.2.2 Chromatography2.1.2.3 Electrophoresis2.1.2.4 Others2.1.3 Software2.2 Service3 Global Proteomics Market (by Application), $Million, 2022-20343.1 Drug Discovery3.2 Clinical Diagnostics3.2.1 Cancer3.2.2 Infectious Disease3.2.3 Others3.3 Others4 Global Proteomics Market (by End User), $Million, 2022-20344.1 Biopharmaceutical Companies4.2 Academic and Research Institutions4.3 Hospitals and Diagnostic Laboratories4.4 Others5 Global Proteomics Market (by Region), $Million, 2022-20345.1 Regional Summary5.2 North America5.2.1 Regional Overview5.2.2 Driving Factors for Market Growth5.2.3 Factors Challenging the Market5.2.4 North America Proteomics Market, by Application5.2.5 North America Proteomics Market, by Offering5.2.5.1 North America Proteomics Market, by Product5.2.6 U.S.5.2.7 Canada5.3 Europe5.4 Asia-Pacific5.5 Latin America5.6 Middle East and Africa6 Global NGS in Proteomics Market6.1 NGS in Proteomics6.1.1 Purpose of NGS in Proteomics6.1.2 Application of NGS in Proteomics6.1.2.1 Advantages of NGS-based Proteomics6.1.2.2 Challenges in NGS-based Proteomics6.1.2.3 Future Trends of NGS in Proteomics6.1.3 NGS in Large-Scale Proteomics6.2 Market Sizing and Forecast6.2.1 By Application6.2.2 By End User7 Markets - Competitive Benchmarking & Company Profiles7.1 Global Proteomics Market: Competitive Landscape7.1.1 Corporate Strategies, January 2022-December 20247.1.2 Partnerships, Alliances, and Business Expansions7.1.3 Mergers and Acquisitions7.1.4 New Offerings7.2 Company Profiles7.2.1 Overview7.2.2 Top Products/Services7.2.3 Top Competitors7.2.4 Target Customers7.2.5 Key Personnel7.2.6 Analyst View Agilent Technologies, Inc. Applied Biomics Biognosys AG Bio-Rad Laboratories, Inc. Danaher Corporation DiaSorin S.p.A. Illumina, Inc. Merck KGaA MS Bioworks Promega Corporation Oxford Expression Technologies Ltd. Revvity, Inc. Standard BioTools Inc. Takara Bio Inc. Thermo Fisher Scientific Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Proteomics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
South China Morning Post
24-05-2025
- Health
- South China Morning Post
On this Chinese island, patients are trying latest experimental drugs for cancer
Beneath the swaying palms of Hainan, China 's tropical southernmost island province, a quiet revolution is unfolding. In the secluded town of Lecheng, a 50-year-old woman sits in a sunlit hospital room, her gaze steady as a nurse administers an injection that could rewrite her future. Diagnosed with early-stage lung cancer , she is among the first patients in China to receive the LK101 injection – a personalised mRNA vaccine designed to slash the risk of relapse Lecheng, an enclave covering 20 sq km (7.7 square miles) on Hainan's eastern coast, is no ordinary town. Dotted with over 30 state-of-the-art hospitals nestled amid lush foliage, it is China's only 'medical special zone', where patients can access therapies still in clinical trials long before they hit the mainstream market. These can range from cutting-edge stem cell treatments to gene therapies. At West China Lecheng Hospital of Sichuan University, where the woman received her vaccine, single-patient suites with floor-to-ceiling windows overlook tropical gardens, a far cry from the crowded, ageing wards typical of mainland public hospitals.
Yahoo
21-05-2025
- Business
- Yahoo
High Content Screening (HCS) Business Analysis Report 2025: Global Market to Reach $2.2 Billion by 2030 - Rising Investments in Biotechnology and Life Sciences Expands Scope
The global High Content Screening (HCS) market is forecast to grow from USD 1.3 billion in 2024 to USD 2.2 billion by 2030, driven by advancements in imaging and personalized medicine. HCS enhances drug discovery by enabling real-time cellular analysis, crucial for cancer research and therapeutic development. Key market segments include Instruments and Consumables with notable growth in regions like the U.S. and China. This report offers insights into market trends, drivers, regional performances, and competitive landscapes, aiding strategic business decisions. High Content Screening (HCS) Market Dublin, May 21, 2025 (GLOBE NEWSWIRE) -- The "High Content Screening (HCS) - Global Strategic Business Report" report has been added to global market for High Content Screening (HCS) was valued at US$1.3 Billion in 2024 and is projected to reach US$2.2 Billion by 2030, growing at a CAGR of 9.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the High Content Screening (HCS) market. High Content Screening (HCS) is revolutionizing the field of biological research and drug discovery by enabling detailed observations of cellular processes in real-time, particularly enhancing the development of personalized medicine. HCS utilizes advanced imaging and analysis techniques to study the effects of various compounds on cells, offering insights far beyond traditional methodologies that used isolated cells. This technique is becoming increasingly pivotal, especially with its application in living multicellular structures like organoids or tissue sections, which more accurately simulate biological interactions within organisms. This nuanced observation at the cellular level allows for a deeper understanding of the cellular dynamics that characterize health and disease states, pushing forward the boundaries of biomedical research and therapeutic the realm of cancer research, HCS has proven invaluable. Traditional models that cultivate tumor cells in artificial environments can induce unnatural behaviors; however, HCS addresses this by using environments that include an extracellular matrix, leading to more natural cellular behavior and responses. This setup allows for the creation of microtissues that closely mimic natural tumor environments, which are then tested against various drugs using automated microscopy and sophisticated image analysis. This phenotypic screening helps to personalize treatment by identifying how individual cells within a tumor respond to specific drugs, highlighting the variability in drug resistance and efficacy. This method significantly refines our understanding of cancer cell dynamics and is instrumental in crafting more effective and personalized treatment regimens, thus minimizing the trial-and-error often associated with cancer integration of HCS into clinical practice, however, faces significant challenges, primarily due to the complexities involved in maintaining accurate 3D cultures and the analysis of large datasets they generate. Despite these hurdles, technological advancements are facilitating the miniaturization of tissue-like structures suitable for high-throughput screening, enhancing the scalability of HCS applications. Key growth drivers for HCS include the integration with multicellular and 3D models, advancements in imaging technologies, and the development of automated analysis software. Additionally, the increasing emphasis on personalized medicine and the expansion of drug discovery efforts demand more effective screening technologies like HCS. Regulatory support for predictive models and consumer demand for quicker, more accurate testing methods also significantly contribute to the broader adoption and ongoing development of HCS, underscoring its growing impact on the fields of drug development and personalized ScopeKey Insights: Market Growth: Understand the significant growth trajectory of the Instruments segment, which is expected to reach US$1.0 Billion by 2030 with a CAGR of a 9.4%. The Consumables segment is also set to grow at 8.2% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $332.6 Million in 2024, and China, forecasted to grow at an impressive 12.3% CAGR to reach $492.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as BD Biosciences, BioTek Instruments Inc., EMD Millipore, Essen BioScience, Evotec AG and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 183 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $1.3 Billion Forecasted Market Value (USD) by 2030 $2.2 Billion Compound Annual Growth Rate 9.2% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Global Economic Update High Content Screening (HCS) - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Demand for Drug Discovery and Development Propels Growth in HCS Market Advances in Imaging Technologies Strengthen Business Case for High Content Screening Adoption Increasing Focus on Personalized Medicine Expands Addressable Market Opportunity for HCS Technological Innovations in Cell-Based Assays Drive Market Growth Growing Use of HCS in Genomics and Proteomics Accelerates Market Penetration Integration of AI and Machine Learning in HCS Throws the Spotlight on Enhanced Data Analysis and Prediction Rising Investment in Biotechnology and Life Sciences Expands Market Scope for HCS Solutions Advances in Miniaturization and Microfluidics Propel Development of High-Performance HCS Systems Focus on Reducing Drug Development Costs and Time-to-Market Spurt Demand for HCS Technologies Increasing Adoption of HCS in Academic and Research Institutions Development of Novel 3D Cell Cultures Expands Addressable Market Opportunity for HCS Advances in Fluorescence and High-Resolution Imaging Propel Growth in Precision Screening Applications Rising Demand for Toxicology Testing and Safety Assessment Drives Adoption of HCS Increasing Use of HCS in Stem Cell Research and Regenerative Medicine Expands Market Reach Development of User-Friendly and Scalable HCS Platforms Fuels Market Adoption Rising Importance of Target-Based and Phenotypic Screening Strengthens Business Case for HCS Growing Adoption of HCS in Cancer Research and Immuno-Oncology Expands Market Scope Focus on Enhancing Screening Efficiency and Throughput Drives Market Innovation FOCUS ON SELECT PLAYERS:Some of the 21 companies featured in this High Content Screening (HCS) market report include: BD Biosciences BioTek Instruments Inc. EMD Millipore Essen BioScience Evotec AG GE Healthcare Life Sciences Genedata AG IntelliCyt Corporation Molecular Devices Inc. PerkinElmer Inc. Thermo Fischer Scientific Inc. TTP LabTech Ltd. Yokogawa Electric Corporation For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment High Content Screening (HCS) Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
21-05-2025
- Business
- Globe and Mail
Gene Transfer Technologies Market to Hit US$5.93 Billion by 2029 with 9.7% CAGR
"The global gene transfer technologies market, valued at US$3.63 billion in 2023, is forecasted to grow at a robust CAGR of 9.7%, reaching US$3.73 billion in 2024 and an impressive US$5.93 billion by 2029" The global gene transfer technologies market, valued at US$3.63 billion in 2023, is forecasted to grow at a robust CAGR of 9.7%, reaching US$3.73 billion in 2024 and an impressive US$5.93 billion by 2029 The global gene transfer technologies market, valued at US$3.63 billion in 2023, is forecasted to grow at a robust CAGR of 9.7%, reaching US$3.73 billion in 2024 and an impressive US$5.93 billion by 2029. The major factors contributing to the growth of the gene transfer technologies market include the growing demand for personalized medicines and cell and gene therapies and investments in gene therapy research. Furthermore, the expanding applications in vaccine development, and cancer immunotherapy in the market is likely to drive market adoption in the coming years. Browse in-depth TOC on " Gene Transfer Technologies Market" 771 - Tables 56 - Figures 524 - Pages The product segment is segmented into instruments, consumables, reagents, kits & assays, and other products. The reagents, kits & assays gene transfer technologies segment dominated product segments owing to various factors such as increasing adoption of gene therapies and cell therapies across pharmaceutical and biotech research. The consumables segment is anticipated to grow at a significant CAGR owing to increase in the activities for research and development in genetic engineering is rising the demand for good quality laboratory materials. The product segment is segmented into instruments, consumables, reagents, kits & assays, and other products. The reagents, kits & assays gene transfer technologies segment dominated product segments owing to various factors such as increasing adoption of gene therapies and cell therapies across pharmaceutical and biotech research. The consumables segment is anticipated to grow at a significant CAGR owing to the surge in research and development activities in genetic engineering, propelling the need for high-quality laboratory materials. The gene transfer technologies market is segmented by mode into viral and non-viral vector. The viral segment dominated the market in 2023. The segment's dominance is attributable to increasing technological developments for cell-based therapies, rising demand for cell and gene therapies, fueled by as a preferred mode of gene delivery. Furthermore, the increasing prevalence of chronic and rare diseases, enhances the adoption of viral vectors. Additionally non-viral vector is also quickly gaining market share due to potential of non-viral systems for precise, targeted genetic modifications without the risks posed by viral vectors. This factor drives the growth of the non-viral segment. Based on the method, the market is divided into ex vivo, in vivo and in vitro. The in vivo method dominated the market in 2023 owing to increased prevalence of genetic disorders and chronic diseases that could heighten demand for innovative therapeutic solutions. Ex vivo method is likely to grow at faster pace owing to commercial success of therapies such as CAR-T cell therapy and stem cell-based treatments for genetic disorders. The application segment is segmented into research, therapeutics, and other applications. The therapeutics application segment dominated application segment in 2023. An increased investment in gene therapies, rising chronic diseases, and need for new approaches in treating these diseases, as well as the advancement of delivery methods which enhance efficacy and safety are supposed to contribute to the growth of this market. The end-user market is categorized into the pharmaceutical & biotechnology companies, academic & research institutes and other end users. The pharmaceutical & biotechnology companies dominated the segment in 2023; the academic & research institutes are likely to grow at a significant CAGR. Favourable regulatory support and strategic partnerships with biotech companies contribute to the growth of end user market. The gene transfer technologies market is split into several regions, such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2023, North America held the largest market share. Moreover, the Asia Pacific region is projected to experience the fastest growth, with a notable compound annual growth rate (CAGR) expected over the forecast period. The growth of the Asia Pacific region is attributable to the increasing investments in biotechnology & pharmaceutical research and rising involvement of pharmaceutical & biotechnology companies. Furthermore, increasing number of collaborations between local and global biotech firms fueling the growth of market. The market for gene transfer technologies market is competitive. Prominent players in the gene transfer technologies market are Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Qiagen (Netherlands), Sartorius AG (Germany), Bio-Rad Laboratories Inc. (US), Revvity (US), Agilent Technologies, Inc (US), Genscript (US) and Bio-Techne (US) and among others. Thermo Fisher Scientific is one of the leaders in gene transfer technologies with extensive product range. The major strengths of the company include diversified product portfolio, strong geographic presence, adoption of organic & inorganic growth strategies and strong emphasis on launching new products in the market contributes to maintaining its dominant position. For instance, in November 2022, Thermo Fisher launched the Gibco CTS AAV-MAX Helper-Free AAV production system to meet clinical and commercial demands for cost-effective and scalable development of adeno-associated virus (AAV)-based gene therapies. Danaher Corporation is one of the dominant players in the global gene transfer technologies market, The company offers various gene transfer technologies through its subsidiary, Cytiva. The company became one of the key players in the biotechnology industry by acquiring Pall Corporation in August 2015 for USD 13.8 billion and the Biopharma business (Cytiva) of GE Healthcare in March 2020 for USD 21 billion. The company focuses on strategic alliances, mergers, and new product introduction. For example, in September 2024, Danaher unveiled the RNA delivery LNP kit specifically designed for use with the NanoAssemblr Ignite and Ignite+ systems, which expands the GenVoy-ILM product line to speed mRNA and saRNA vaccine development. Merck KGaA is also one of the leading firms in gene transfer technologies market. The company operates in the gene transfer technologies market through its life science business segment. The company's leading position is attributable to its diversified product portfolio, strong geographic presence, and adoption of organic and inorganic growth strategies. For instance, in August 2024, Merck KGaA acquired Mirus Bio (US) to advance Merck's integrated offering for viral vector manufacturing. For more information, Inquire Now!
